Loading
אופקו is a listed company. Its directors and officers file their transactions with TASE (ISA). From 18 October 2025 to 18 October 2026, the disclosure feed for אופקו logged 15 filings by 13 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Over the last twelve months, not one insider purchase of אופקו stock was filed.
Across the 530 companies tracked on its exchange, the median is 14 filings; at 15 filings, this issuer sits above that mark.
These figures are compiled from regulatory filings published by TASE (ISA). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
15 of 15 declarations
Opko is a publicly traded company on the Tel Aviv Stock Exchange, specializing in the health and biotechnology sector. It focuses on the development of innovative diagnostics and treatments.